Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CARM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CARM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CARM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CARM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:003052021 | Liver | HCC | intracellular estrogen receptor signaling pathway | 35/7958 | 54/18723 | 7.73e-04 | 4.65e-03 | 35 |
GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:1905214 | Liver | HCC | regulation of RNA binding | 10/7958 | 12/18723 | 4.79e-03 | 2.02e-02 | 10 |
GO:001635811 | Liver | HCC | dendrite development | 121/7958 | 243/18723 | 1.26e-02 | 4.56e-02 | 121 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:005109820 | Oral cavity | OSCC | regulation of binding | 212/7305 | 363/18723 | 3.88e-14 | 2.15e-12 | 212 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:003052218 | Oral cavity | OSCC | intracellular receptor signaling pathway | 149/7305 | 265/18723 | 8.69e-09 | 1.81e-07 | 149 |
GO:007138318 | Oral cavity | OSCC | cellular response to steroid hormone stimulus | 112/7305 | 204/18723 | 2.82e-06 | 3.47e-05 | 112 |
GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
GO:004340116 | Oral cavity | OSCC | steroid hormone mediated signaling pathway | 76/7305 | 136/18723 | 4.76e-05 | 3.99e-04 | 76 |
GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
GO:00456006 | Oral cavity | OSCC | positive regulation of fat cell differentiation | 41/7305 | 66/18723 | 1.20e-04 | 8.60e-04 | 41 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:19052141 | Oral cavity | OSCC | regulation of RNA binding | 11/7305 | 12/18723 | 2.45e-04 | 1.57e-03 | 11 |
GO:00331437 | Oral cavity | OSCC | regulation of intracellular steroid hormone receptor signaling pathway | 44/7305 | 74/18723 | 2.89e-04 | 1.82e-03 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CARM1 | SNV | Missense_Mutation | novel | c.687C>A | p.Asn229Lys | p.N229K | Q86X55 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CARM1 | SNV | Missense_Mutation | | c.608N>T | p.Ala203Val | p.A203V | Q86X55 | protein_coding | tolerated(0.74) | benign(0.111) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1560N>C | p.Leu520Phe | p.L520F | Q86X55 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.991) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.950N>T | p.Ser317Phe | p.S317F | Q86X55 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-E9-A1RG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
CARM1 | insertion | Nonsense_Mutation | novel | c.377_378insACAGGCATAAGCCACCGTGCCCGGCTTATTATTTCTTGTAGAGA | p.Cys127GlnfsTer3 | p.C127Qfs*3 | Q86X55 | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CARM1 | SNV | Missense_Mutation | novel | c.1255N>T | p.Arg419Trp | p.R419W | Q86X55 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CARM1 | SNV | Missense_Mutation | | c.330N>C | p.Gln110His | p.Q110H | Q86X55 | protein_coding | tolerated(0.09) | benign(0.106) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD |
CARM1 | SNV | Missense_Mutation | rs765573504 | c.1204N>A | p.Val402Met | p.V402M | Q86X55 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1430C>T | p.Thr477Met | p.T477M | Q86X55 | protein_coding | deleterious(0.01) | possibly_damaging(0.814) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CARM1 | SNV | Missense_Mutation | | c.1134N>T | p.Met378Ile | p.M378I | Q86X55 | protein_coding | tolerated(0.35) | benign(0.035) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 336446915 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | | EOSIN | EOSIN | 18348515 |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103610 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 310264736 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661334 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 178103609 | | |
10498 | CARM1 | ENZYME, METHYL TRANSFERASE, DRUGGABLE GENOME | inhibitor | 315661333 | BIIB021 | |